在GLP-1时代的行为医学
1Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095, United States.
概括
葡萄糖类-1 (GLP-1) 激动剂提供了显著的减肥益处,但可能会使体重变得医学化并增加耻辱感. 行为医学应该专注于健康标志物,而不仅仅是BMI,以获得包容性护理.
科学领域:
- 行为医学是一种行为医学.
- 健康心理学 心理健康心理学
- 医学伦理 医学伦理
背景情况:
- 葡萄糖类-1 (GLP-1) 激动剂药物越来越多地被认为具有显著的减肥效应.
- 这些药物对行为医学和健康心理学专业人士来说存在复杂的考虑因素.
- 潜在的好处包括超越减肥的改善健康结果和减轻体重管理的耻辱感.
研究的目的:
- 在行为医学和健康心理学中批判性地检查GLP-1激动剂药物的多方面的影响.
- 探索与这些强大的减肥药物相关的优势和潜在风险.
- 倡导一种细微的方法来将它们纳入临床实践和研究.
主要方法:
- 这是一个评论,而不是经验研究. 作者综合了现有的知识和观点.
- 讨论涉及从临床,社会和伦理角度分析GLP-1激动剂的积极和消极方面.
- 考虑社会身份理论和包括体重的护理模型为分析提供了信息.
主要成果:
- GLP-1激动剂显示出独立于减肥的健康改善的希望.
- 潜在的风险包括体重的医疗化,体重耻辱的增加,以及将GLP-1s视为"简单的出路"的看法.
- 从社会身份的角度来看,GLP-1s可以被看作是针对体重较高的个体.
结论:
- 临床护理应采用以患者为中心,包括体重在内的方法,根据个人健康和社会背景量身定制治疗.
- 行为医学研究应该优先考虑针对健康标志物和行为的干预措施,而不仅仅关注BMI减少.
- 这种转变将提高健康结果,无论患者的体重或药物状况如何.
相关概念视频
01:24Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
01:06Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
01:15Diabetes: Management and Pharmacotherapy
235
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
235
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159